{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:59:27Z","timestamp":1775059167949,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00277-023-05500-2","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T08:02:46Z","timestamp":1698220966000},"page":"3603-3611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms"],"prefix":"10.1007","volume":"102","author":[{"given":"Xinhui","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongye","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yigeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"5500_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.blre.2018.11.001","volume":"34","author":"EA Copelan","year":"2019","unstructured":"Copelan EA, Chojecki A, Lazarus HM, Avalos BR (2019) Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Rev 34:34\u201344","journal-title":"Blood Rev"},{"key":"5500_CR2","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3390\/cancers15051609","volume":"15","author":"T Caballero-Vel\u00e1zquez","year":"2023","unstructured":"Caballero-Vel\u00e1zquez T et al (2023) Prognostic value of measurable residual disease in patients with AML undergoing HSCT: a multicenter study. Cancers 15:1609","journal-title":"Cancers"},{"key":"5500_CR3","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1038\/s41409-021-01450-3","volume":"56","author":"AM Jimenez","year":"2021","unstructured":"Jimenez AM et al (2021) An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplant 56:3068\u20133077","journal-title":"Bone Marrow Transplant"},{"key":"5500_CR4","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M et al (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol Off J Am Soc Clin Oncol 28:3730\u20133738","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5500_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL et al (2017) Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol Off J Am Soc Clin Oncol 35:1154\u20131161","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5500_CR6","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A et al (2020) Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant 55:1114\u20131125","journal-title":"Bone Marrow Transplant"},{"key":"5500_CR7","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang DCS (2021) BCL2 and MCL1 inhibitors for hematologic malignancies. Blood 138:1120\u20131136","journal-title":"Blood"},{"key":"5500_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bjh.14684","volume":"178","author":"M Vogler","year":"2017","unstructured":"Vogler M, Walter HS, Dyer MJS (2017) Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment. Br J Haematol 178:364\u2013379","journal-title":"Br J Haematol"},{"key":"5500_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/10428194.2014.910657","volume":"56","author":"JM Bogenberger","year":"2015","unstructured":"Bogenberger JM et al (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226\u2013229","journal-title":"Leuk Lymphoma"},{"key":"5500_CR10","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.2147\/CMAR.S316561","volume":"13","author":"J Tong","year":"2021","unstructured":"Tong J et al (2021) Efficacy of venetoclax combined with decitabine-based treatment for heavily pre-treated relapsed or refractory AML patients in a real-world setting. Cancer Manag Res 13:5613\u20135621","journal-title":"Cancer Manag Res"},{"key":"5500_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11096-014-0036-5","volume":"37","author":"X Cai","year":"2015","unstructured":"Cai X et al (2015) A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies. Int J Clin Pharmacol 37:44\u201352","journal-title":"Int J Clin Pharmacol"},{"key":"5500_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/ejh.13925","volume":"110","author":"X Zheng","year":"2023","unstructured":"Zheng X et al (2023) Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 110:527\u2013533","journal-title":"Eur J Haematol"},{"key":"5500_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bbmt.2019.09.001","volume":"26","author":"Y-G Cao","year":"2020","unstructured":"Cao Y-G et al (2020) Conditioning regimen of 5-day decitabine administration for allogeneic stem cell transplantation in patients with myelodysplastic syndrome and myeloproliferative neoplasms. Biol Blood Marrow Transplant 26:285\u2013291","journal-title":"Biol Blood Marrow Transplant"},{"key":"5500_CR14","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"MH Gilleece","year":"2018","unstructured":"Gilleece MH et al (2018) Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol 93:1142\u20131152","journal-title":"Am J Hematol"},{"key":"5500_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.18632\/oncotarget.28193","volume":"13","author":"BC Valdez","year":"2022","unstructured":"Valdez BC et al (2022) ABT199\/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells. Oncotarget 13:319\u2013330","journal-title":"Oncotarget"},{"key":"5500_CR16","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","volume":"5","author":"JS Garcia","year":"2021","unstructured":"Garcia JS et al (2021) Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv 5:5536\u20135545","journal-title":"Blood Adv"},{"key":"5500_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee JB et al (2021) Venetoclax enhances T cell\u2013mediated antileukemic activity by increasing ROS production. Blood 138:234\u2013245","journal-title":"Blood"},{"key":"5500_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/07853890.2022.2164610","volume":"55","author":"X Cao","year":"2023","unstructured":"Cao X et al (2023) Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML. Ann Med 55:388\u2013400","journal-title":"Ann Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05500-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05500-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05500-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:06:09Z","timestamp":1699679169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05500-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["5500"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05500-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"assertion":[{"value":"8 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by our center\u2019s Institutional Review Board.Consent for publicationConsent for publication was obtained from the patient. All patients provided written formed consent. This study does not include data which require permission to reproduce material from other sources.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}